Medication Pearl of the Day: Kcentra [Prothrombin Complex Concentrate (Human)]
Indication: Kcentra [prothrombin complex concentrate (human)], is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g., warfarin) therapy in adult patients with acute major bleeding.
- Dosing: 20 to 50 units/kg, do not exceed 2500 to 5000 units.
- Dosage forms: Kcentra is available as a single-use vial containing coagulation factors II, VII, IX and X, and antithrombotic proteins C and S as a lyophilized concentrate.
- Adverse events: The most common adverse reactions (frequency ≥2.8%) observed in subjects receiving Kcentra were headache, nausea/vomiting, arthralgia, and hypotension.
- Mechanism of action: Kcentra contains the vitamin K-dependent coagulation factors II (FII), VII (FVII), IX (FIX), and X (FX), together known as the prothrombin complex, and the antithrombotic protein C and protein S. If the patient has an acquired coagulation factor deficiency where one or more of the vitamin K-dependent coagulation factors are deficient, bleeding may occur.
Source: Kcentra Product Labeling (fda.gov)